Small Animal Imaging Facility Shared Resource

项目总结/摘要 在威斯康星州大学Carbone癌症中心（UWCCC）下运作的小动物成像 设施（SAIF）提供创新的，具有成本效益的，高分辨率的成像支持UWCCC成员， 在研究中使用小动物模型。学院领导和设施经理提供指导， 研究人员确保成像方式和实验设计最适合解决他们的癌症 问题正电子发射/计算机断层扫描（PET/CT），磁共振成像（MRI）， 超声（US）、光声和/或光学生物发光/荧光/近红外（NIR）成像 通过SAIF，可以获得所有主要的小动物成像模式。此外，UWCCC 研究者可以选择他们所需的服务水平，从图像采集，重建， 以及从解释到分析和/或演示幻灯片准备。必要时，商业或专有 为研究者获取成像剂，并在使用前确保其质量。SAIF拿着雨伞 动物使用、生物安全和辐射安全协议，从而确保成像的适当监管控制 研究，同时最大限度地减少对个体研究者的监管负担。位于邻近类似 临床研究扫描仪，SAIF致力于设计新成像剂的临床前成像评估 最终的临床转化。一种这样的药剂，CLR1404，经历了广泛的临床前评价 在SAIF内，在转化为8个临床成像和放射治疗试验之前。在当前CCSG供资期间， SAIF已经为65个UWCCC成员提供了关键的成像支持，这些成员代表了所有六个 UWCCC项目。我们继续评估新的成像和相关技术，如果合适和相关， 向会员国提出建议，制定一项计划，将这些新技术引入该设施。我们的具体目标是：1） 为UWCCC成员提供最先进的小动物癌症成像的无缝访问和指导 新疗法的基本临床前评估技术; 2）提供临床前发现和 开发支持新的分子成像和扩散剂。CCSG提供的资金 在支持我们的使命，以尽可能高的水平为UWCCC成员服务，同时最大限度地减少 在一个相对昂贵的以技术为中心的领域的成本。我们希望我们在发展和评估中的作用 新的成像和治疗剂，特别是那些正在开发的我们自己的成员，以及 通过成像评估新的治疗剂，最终将允许个性化的治疗计划， 改善癌症患者的生活质量和生存结果。

PROJECT SUMMARY/ABSTRACT Operating under the University of Wisconsin Carbone Cancer Center (UWCCC), the Small Animal Imaging Facility (SAIF) provides innovative, cost effective, high-resolution imaging support to UWCCC members who utilize small animal models in their research. The Faculty Leader and Facility Manager provide guidance to investigators ensuring the imaging modality and experimental design are best suited to address their cancer question. Incorporating positron emission/computed tomography (PET/CT), magnetic resonance imaging (MRI), ultrasound (US), photoacoustics, and/or optical bioluminescence/fluorescence/near-infrared (NIR) imaging modalities, the SAIF affords access to all major small animal imaging modalities. Moreover, UWCCC investigators can select their desired level of service deliverables ranging from image acquisition, reconstruction, and interpretation to analysis, and/or presentation slide preparation. When necessary, commercial or proprietary imaging agents are acquired for investigators and their quality ensured prior to use. The SAIF holds umbrella animal use, biosafety, and radiation safety protocols thus assuring appropriate regulatory control of imaging studies while minimizing the regulatory burden placed on individual investigators. Located adjacent to similar clinical research scanners, the SAIF strives to design preclinical imaging assessment of new imaging agents with eventual clinical translation in mind. One such agent, CLR1404, underwent extensive preclinical evaluation within the SAIF prior to translating into 8 clinical imaging and radiotherapy trials. During the current CCSG funding cycle, the SAIF has provided critical imaging support to 65 unique UWCCC members representing all six UWCCC programs. We continue to assess new imaging and related technologies and, if suitable and relevant to the membership, develop a plan to bring such new technologies into the facility. Our specific aims are to; 1) provide UWCCC members seamless access and guidance to the most advanced small animal cancer imaging technologies for essential preclinical assessment of new therapies; and 2) to provide preclinical discovery and development support for new molecular imaging and diapeutic agents. Funding provided from the CCSG is critical in supporting our mission to serve the UWCCC membership at the highest level possible while minimizing costs in a relatively expensive technology-centric field. We expect that our role in the development and evaluation of new imaging and therapy agents, especially those being developed by our own membership, as well as the assessment of new therapeutic agents via imaging, will ultimately permit personalized treatment planning and improve the quality of life and survival outcomes of cancer patients.